Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: A randomized, placebo-controlled trial, ACTG 307

Ian Frank, Ronald J. Bosch, Susan Fiscus, Fred Valentine, Charles Williams Flexner, Yoninah Segal, Ping Ruan, Roy Gulick, Kenneth Wood, Scharla Estep, Lawrence Fox, Thomas Nevin, Michael Stevens, Joseph J. Eron

Research output: Contribution to journalArticle

Abstract

We performed a 24-week, placebo-controlled, comparative trial of hydrosyurea (HU) monotherapy, didanosine (ddl) monotherapy, and the combination of ddI plus HU administered as 1000 mg qd or 1500 mg qd in antiretroviral-naive and experienced subjects with CD4+ lymphocyte counts of 200-700 cells/mm3. Enrollment included 134 subjects. HU enhanced the antiviral activity of ddI by 1.0 log10 copies/ml after 8 weeks of therapy, with sustained responses over 24 weeks. HU alone over 4 weeks had no effect. Lamivudine resistance had little impact on antiretroviral activity when examined across treatment arms. Increases in absolute CD4+ T cell counts, but not CD4+ T cell percentages, were less in subjects who received HU compared to ddI monotherapy, and lymphoproliferative responses to antigenic and mitogenic stimuli were not altered. Subjects who received HU 1500 mg were more likely to experience dose-limiting hematological toxicities compared to those who received 1000 mg, without any additional antiviral benefit. HU may continue to have a role as a component of HIV therapy.

Original languageEnglish (US)
Pages (from-to)916-926
Number of pages11
JournalAIDS Research and Human Retroviruses
Volume20
Issue number9
DOIs
StatePublished - Sep 2004

Fingerprint

Didanosine
Hydroxyurea
HIV-1
Randomized Controlled Trials
Placebos
CD4 Lymphocyte Count
Safety
T-Lymphocytes
Lamivudine
Antiviral Agents
Therapeutics
HIV

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects : A randomized, placebo-controlled trial, ACTG 307. / Frank, Ian; Bosch, Ronald J.; Fiscus, Susan; Valentine, Fred; Flexner, Charles Williams; Segal, Yoninah; Ruan, Ping; Gulick, Roy; Wood, Kenneth; Estep, Scharla; Fox, Lawrence; Nevin, Thomas; Stevens, Michael; Eron, Joseph J.

In: AIDS Research and Human Retroviruses, Vol. 20, No. 9, 09.2004, p. 916-926.

Research output: Contribution to journalArticle

Frank, Ian ; Bosch, Ronald J. ; Fiscus, Susan ; Valentine, Fred ; Flexner, Charles Williams ; Segal, Yoninah ; Ruan, Ping ; Gulick, Roy ; Wood, Kenneth ; Estep, Scharla ; Fox, Lawrence ; Nevin, Thomas ; Stevens, Michael ; Eron, Joseph J. / Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects : A randomized, placebo-controlled trial, ACTG 307. In: AIDS Research and Human Retroviruses. 2004 ; Vol. 20, No. 9. pp. 916-926.
@article{968b0cced03d446eb429947404cf1af2,
title = "Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: A randomized, placebo-controlled trial, ACTG 307",
abstract = "We performed a 24-week, placebo-controlled, comparative trial of hydrosyurea (HU) monotherapy, didanosine (ddl) monotherapy, and the combination of ddI plus HU administered as 1000 mg qd or 1500 mg qd in antiretroviral-naive and experienced subjects with CD4+ lymphocyte counts of 200-700 cells/mm3. Enrollment included 134 subjects. HU enhanced the antiviral activity of ddI by 1.0 log10 copies/ml after 8 weeks of therapy, with sustained responses over 24 weeks. HU alone over 4 weeks had no effect. Lamivudine resistance had little impact on antiretroviral activity when examined across treatment arms. Increases in absolute CD4+ T cell counts, but not CD4+ T cell percentages, were less in subjects who received HU compared to ddI monotherapy, and lymphoproliferative responses to antigenic and mitogenic stimuli were not altered. Subjects who received HU 1500 mg were more likely to experience dose-limiting hematological toxicities compared to those who received 1000 mg, without any additional antiviral benefit. HU may continue to have a role as a component of HIV therapy.",
author = "Ian Frank and Bosch, {Ronald J.} and Susan Fiscus and Fred Valentine and Flexner, {Charles Williams} and Yoninah Segal and Ping Ruan and Roy Gulick and Kenneth Wood and Scharla Estep and Lawrence Fox and Thomas Nevin and Michael Stevens and Eron, {Joseph J.}",
year = "2004",
month = "9",
doi = "10.1089/aid.2004.20.916",
language = "English (US)",
volume = "20",
pages = "916--926",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects

T2 - A randomized, placebo-controlled trial, ACTG 307

AU - Frank, Ian

AU - Bosch, Ronald J.

AU - Fiscus, Susan

AU - Valentine, Fred

AU - Flexner, Charles Williams

AU - Segal, Yoninah

AU - Ruan, Ping

AU - Gulick, Roy

AU - Wood, Kenneth

AU - Estep, Scharla

AU - Fox, Lawrence

AU - Nevin, Thomas

AU - Stevens, Michael

AU - Eron, Joseph J.

PY - 2004/9

Y1 - 2004/9

N2 - We performed a 24-week, placebo-controlled, comparative trial of hydrosyurea (HU) monotherapy, didanosine (ddl) monotherapy, and the combination of ddI plus HU administered as 1000 mg qd or 1500 mg qd in antiretroviral-naive and experienced subjects with CD4+ lymphocyte counts of 200-700 cells/mm3. Enrollment included 134 subjects. HU enhanced the antiviral activity of ddI by 1.0 log10 copies/ml after 8 weeks of therapy, with sustained responses over 24 weeks. HU alone over 4 weeks had no effect. Lamivudine resistance had little impact on antiretroviral activity when examined across treatment arms. Increases in absolute CD4+ T cell counts, but not CD4+ T cell percentages, were less in subjects who received HU compared to ddI monotherapy, and lymphoproliferative responses to antigenic and mitogenic stimuli were not altered. Subjects who received HU 1500 mg were more likely to experience dose-limiting hematological toxicities compared to those who received 1000 mg, without any additional antiviral benefit. HU may continue to have a role as a component of HIV therapy.

AB - We performed a 24-week, placebo-controlled, comparative trial of hydrosyurea (HU) monotherapy, didanosine (ddl) monotherapy, and the combination of ddI plus HU administered as 1000 mg qd or 1500 mg qd in antiretroviral-naive and experienced subjects with CD4+ lymphocyte counts of 200-700 cells/mm3. Enrollment included 134 subjects. HU enhanced the antiviral activity of ddI by 1.0 log10 copies/ml after 8 weeks of therapy, with sustained responses over 24 weeks. HU alone over 4 weeks had no effect. Lamivudine resistance had little impact on antiretroviral activity when examined across treatment arms. Increases in absolute CD4+ T cell counts, but not CD4+ T cell percentages, were less in subjects who received HU compared to ddI monotherapy, and lymphoproliferative responses to antigenic and mitogenic stimuli were not altered. Subjects who received HU 1500 mg were more likely to experience dose-limiting hematological toxicities compared to those who received 1000 mg, without any additional antiviral benefit. HU may continue to have a role as a component of HIV therapy.

UR - http://www.scopus.com/inward/record.url?scp=5644227530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5644227530&partnerID=8YFLogxK

U2 - 10.1089/aid.2004.20.916

DO - 10.1089/aid.2004.20.916

M3 - Article

C2 - 15597521

AN - SCOPUS:5644227530

VL - 20

SP - 916

EP - 926

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 9

ER -